These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9500624)

  • 21. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
    Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
    Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: an insight from MOST, a multinational observational study.
    Salvadori M; Rosati A; Bertoni E; Bock A; Chapman J; Dussol B; Fritsche L; Kliem V; Lebranchu Y; Oppenheimer F; Pohanka E; Tufveson G; Soergel M
    Transplant Proc; 2006 May; 38(4):1010-3. PubMed ID: 16757247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation.
    MacPhee IA; Bradley JA; Briggs JD; Junor BJ; MacPherson SG; McMillan MA; Rodger RS; Watson MA
    Transplantation; 1998 Nov; 66(9):1186-92. PubMed ID: 9825816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.
    Mourad G; Vela C; Ribstein J; Mimran A
    Transplantation; 1998 Mar; 65(5):661-7. PubMed ID: 9521200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients.
    Vincenti F; Mendez R; Curtis J; Light J; Pearson T; Wu YM; Katz SM; Akalin E; Esterl R; Gugliuzza K; Shihab F; Jordan S; Jonsson J; Molmenti E; Barbeito R
    Transplantation; 2005 Oct; 80(7):910-6. PubMed ID: 16249738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study.
    Mourad G; Rostaing L; Legendre Ch;
    Transplant Proc; 2005 Mar; 37(2):920-2. PubMed ID: 15848575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion.
    Citterio F; Scatà MC; Romagnoli J; Nanni G; Castagneto M
    Transplantation; 2005 Apr; 79(7):802-6. PubMed ID: 15818322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion.
    Pescovitz MD; First MR
    Transpl Int; 1998; 11 Suppl 1():S94-7. PubMed ID: 9664953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.
    Dunn S; Cooney G; Sommerauer J; Lindsay C; McDiarmid S; Wong RL; Chang CT; Smith HT; Choc MG
    Transplantation; 1997 Jun; 63(12):1762-7. PubMed ID: 9210501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients.
    Rostaing L; Mourad G; Kamar N; Garrigue V; Karras A; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Berthoux F; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Legendre C;
    Transplant Proc; 2006 Nov; 38(9):2860-3. PubMed ID: 17112849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
    Vincenti F; Friman S; Scheuermann E; Rostaing L; Jenssen T; Campistol JM; Uchida K; Pescovitz MD; Marchetti P; Tuncer M; Citterio F; Wiecek A; Chadban S; El-Shahawy M; Budde K; Goto N;
    Am J Transplant; 2007 Jun; 7(6):1506-14. PubMed ID: 17359512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A; Shekhar C; Heer M; Minz M
    Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N; Rodger RS; McMillan MA; Junor BJ
    Transplantation; 2007 Mar; 83(5):582-7. PubMed ID: 17353778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):968-70. PubMed ID: 8623168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.